Form 8-K Spark Therapeutics, Inc. For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson Humphrey
August 7, 2018 3:32 PM EDTSunTrust Robinson Humphrey lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $61.00 (from $102.00) while maintaining a Buy rating.
Analsyt Edward Nash commented, "Updated data from hemophilia A program dims outlook as shares tumble 28% intraday (vs S&P50 up 0.3%). While the mean... More
Spark Therapeutics (ONCE) PT Lowered to $80 at Cowen
August 7, 2018 3:31 PM EDTCowen lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $80.00 (from $90.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Spark reported Q2 financials and provided an update on the SPK-8011 clinical program. Five of seven patients treated with... More
Spark Therapeutics (ONCE) PT Lowered to $64 at RBC Capital
August 7, 2018 2:31 PM EDTRBC Capital lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $64.00 (from $75.00) while maintaining a Sector Perform rating.
Analyst Kennen MacKay said the view today's SPK-8011 update suggestive of efficacy and safety below investor expectations and expect the stock to be choppy into ASH data detailing today's update.
... MoreCantor Fitzgerald Defends Spark Therapeutics (ONCE), Saying They Didn't Expect Perfection
August 7, 2018 9:34 AM EDTCantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected perfection, they didn't.
Piros commented, "We reiterate our Overweight rating and 12-month PT of $103 on Spark Therapeutics following 2Q18 financial results and program... More
